SELLAS Life Sciences amends executive severance and change-of-control agreements
SELLAS Life Sciences Group amended its CEO's employment agreement and entered amended severance agreements with its CFO and Chief Development Officer, all dated June 24, 2026. The changes set out payment terms if these executives are terminated, including enhanced change-of-control benefits, and the filing does not report any change in executive roles.
Key points
- CEO Dr. Angelos Stergiou's change-in-control severance payments will be paid as a lump sum under an amendment to his employment agreement.
- CFO John Burns and Dr. Dragan Cicic received amended agreements; within one month before or one year after a change of control, each is entitled to a lump sum of 15 months' base salary plus target bonus.
- Outside a change-of-control period, severance is nine months of base salary, pro rata target bonus paid over nine months, and up to nine months of COBRA reimbursement.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.